Pharmaceutical compounds that target essential components of the circadian clock, such as GSK-3β inhibitors, CRY stabilizers, CRY inhibitors, CK1 inhibitors, CK2 inhibitors, and REV-ERB agonists, are being developed and show anti-cancer potential (47, 48). The gene discussed is CRYL1; the disease is cancer.